Jpmorgan Chase & CO Neu Base Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$0.41 - $1.3 $10 - $32
25 New
25 $0
Q4 2021

Feb 10, 2022
SELL
$2.6 - $4.18 $1,001 - $1,609
-385 Closed
0 $0
Q3 2021

Nov 12, 2021
BUY
$3.27 - $4.76 $1,258 - $1,832
385 New
385 $1,000

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email